

Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2016

Consolidated Statement of Income

Ono Pharmaceutical Co., Ltd. and Consolidated Subsidiaries

	Millions of yen		Thousands of US\$
	Year ended March 31, 2015	Year ended March 31, 2016	Year ended March 31, 2016
Revenue	¥ 135,775	¥ 160,284	\$ 1,431,108
Cost of sales	(35,136)	(41,524)	(370,752)
Gross profit	100,639	118,760	1,060,356
Selling, general, and administrative expenses	(42,222)	(43,979)	(392,671)
Research and development costs	(41,346)	(43,369)	(387,222)
Other income	368	708	6,320
Other expenses	(2,645)	(1,612)	(14,396)
Operating profit	14,794	30,507	272,387
Finance income	3,565	3,088	27,568
Finance costs	(67)	(291)	(2,600)
Share of profit (loss) from investments in associates	13	(32)	(286)
Profit before tax	18,305	33,272	297,069
Income tax expense	(5,089)	(8,080)	(72,140)
Profit for the year	13,216	25,192	224,928
Profit for the year attributable to:			
Owners of the parent company	12,976	24,979	223,028
Non-controlling interests	240	213	1,901
Profit for the year	13,216	25,192	224,928
Earnings per share:		Yen	US\$
Basic earnings per share	24.48	47.13	0.42
Diluted earnings per share	-	47.13	0.42

(Note) The company conducted a stock split of common stocks at a ratio of 1:5 with an effective date of April 1, 2016. As for “Basic earnings per share” and “Diluted earnings per share”, it is calculated assuming that the stock split was conducted at the beginning of the previous fiscal year.